Ganglioside treatment in diabetic peripheral neuropathy: A multicenter trial

Gaetano Crepaldi, Domenico Fedele, Antonio Tiengo, Leontino Battistin, Paolo Negrin, Guido Pozza, Nicola Canal, Gian Carlo Comi, Gianfranco Lenti, Gianfranco Pagano, Ludovico Bergamini, Walter Troni, Francesco Frigato, Cesare Ravenna, Corrado Mezzina, Roberta Gallato, Danilo Massari, Marino Massarotti, Rita Matano, Francesco GrigolettoHank Davis, Monroe Klein

Research output: Contribution to journalArticle

Abstract

Ganglioside treatment was evaluated with a multicenter, randomized, double-blind, controlled, cross-over vs placebo trial in 140 insulin-treated diabetic subjects with peripheral neuropathy. The patients entered the study when they showed an impairment in at least two of the electroneurographic parameters, and were assigned to two protocols according to the presence and severity of their neurological symptoms. Ninety-seven diabetic subjects with no or mild symptoms were assigned to protocol I, whereas 43 symptomatic patients were assigned to protocol II. The treatment periods lasted 6 weeks with an intermediate washout period of 4 weeks. The treatment consisted in the daily i.m. administration of 20 mg gangliosides or of placebo. Electroneurographic parameters were recorded at the beginning and at the end of each treatment period, whereas clinical and metabolic data (mean daily plasma glucose, glycosuria and glycosylated hemoglobin) were evaluated every three weeks in protocol I and every two weeks in protocol II. No change in the metabolic parameters was observed throughout the trial period. However, the treatment induced a statistically significant improvement of paresthesias (protocol II) and of some electrophysiological parameters; in particular, ganglioside treatment improved MCV of peroneal nerve (p

Original languageEnglish
Pages (from-to)265-276
Number of pages12
JournalActa Diabetologica Latina
Volume20
Issue number3
DOIs
Publication statusPublished - Jul 1983

Fingerprint

Diabetic Neuropathies
Gangliosides
Peripheral Nervous System Diseases
Multicenter Studies
Therapeutics
Placebos
Glycosuria
Peroneal Nerve
Paresthesia
Glycosylated Hemoglobin A
Insulin
Glucose

Keywords

  • Diabetic neuropathy
  • Gangliosides
  • Nerve conduction velocity

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Crepaldi, G., Fedele, D., Tiengo, A., Battistin, L., Negrin, P., Pozza, G., ... Klein, M. (1983). Ganglioside treatment in diabetic peripheral neuropathy: A multicenter trial. Acta Diabetologica Latina, 20(3), 265-276. https://doi.org/10.1007/BF02581271

Ganglioside treatment in diabetic peripheral neuropathy : A multicenter trial. / Crepaldi, Gaetano; Fedele, Domenico; Tiengo, Antonio; Battistin, Leontino; Negrin, Paolo; Pozza, Guido; Canal, Nicola; Comi, Gian Carlo; Lenti, Gianfranco; Pagano, Gianfranco; Bergamini, Ludovico; Troni, Walter; Frigato, Francesco; Ravenna, Cesare; Mezzina, Corrado; Gallato, Roberta; Massari, Danilo; Massarotti, Marino; Matano, Rita; Grigoletto, Francesco; Davis, Hank; Klein, Monroe.

In: Acta Diabetologica Latina, Vol. 20, No. 3, 07.1983, p. 265-276.

Research output: Contribution to journalArticle

Crepaldi, G, Fedele, D, Tiengo, A, Battistin, L, Negrin, P, Pozza, G, Canal, N, Comi, GC, Lenti, G, Pagano, G, Bergamini, L, Troni, W, Frigato, F, Ravenna, C, Mezzina, C, Gallato, R, Massari, D, Massarotti, M, Matano, R, Grigoletto, F, Davis, H & Klein, M 1983, 'Ganglioside treatment in diabetic peripheral neuropathy: A multicenter trial', Acta Diabetologica Latina, vol. 20, no. 3, pp. 265-276. https://doi.org/10.1007/BF02581271
Crepaldi G, Fedele D, Tiengo A, Battistin L, Negrin P, Pozza G et al. Ganglioside treatment in diabetic peripheral neuropathy: A multicenter trial. Acta Diabetologica Latina. 1983 Jul;20(3):265-276. https://doi.org/10.1007/BF02581271
Crepaldi, Gaetano ; Fedele, Domenico ; Tiengo, Antonio ; Battistin, Leontino ; Negrin, Paolo ; Pozza, Guido ; Canal, Nicola ; Comi, Gian Carlo ; Lenti, Gianfranco ; Pagano, Gianfranco ; Bergamini, Ludovico ; Troni, Walter ; Frigato, Francesco ; Ravenna, Cesare ; Mezzina, Corrado ; Gallato, Roberta ; Massari, Danilo ; Massarotti, Marino ; Matano, Rita ; Grigoletto, Francesco ; Davis, Hank ; Klein, Monroe. / Ganglioside treatment in diabetic peripheral neuropathy : A multicenter trial. In: Acta Diabetologica Latina. 1983 ; Vol. 20, No. 3. pp. 265-276.
@article{d2691aea56f6428bbb5e0e9471b96744,
title = "Ganglioside treatment in diabetic peripheral neuropathy: A multicenter trial",
abstract = "Ganglioside treatment was evaluated with a multicenter, randomized, double-blind, controlled, cross-over vs placebo trial in 140 insulin-treated diabetic subjects with peripheral neuropathy. The patients entered the study when they showed an impairment in at least two of the electroneurographic parameters, and were assigned to two protocols according to the presence and severity of their neurological symptoms. Ninety-seven diabetic subjects with no or mild symptoms were assigned to protocol I, whereas 43 symptomatic patients were assigned to protocol II. The treatment periods lasted 6 weeks with an intermediate washout period of 4 weeks. The treatment consisted in the daily i.m. administration of 20 mg gangliosides or of placebo. Electroneurographic parameters were recorded at the beginning and at the end of each treatment period, whereas clinical and metabolic data (mean daily plasma glucose, glycosuria and glycosylated hemoglobin) were evaluated every three weeks in protocol I and every two weeks in protocol II. No change in the metabolic parameters was observed throughout the trial period. However, the treatment induced a statistically significant improvement of paresthesias (protocol II) and of some electrophysiological parameters; in particular, ganglioside treatment improved MCV of peroneal nerve (p",
keywords = "Diabetic neuropathy, Gangliosides, Nerve conduction velocity",
author = "Gaetano Crepaldi and Domenico Fedele and Antonio Tiengo and Leontino Battistin and Paolo Negrin and Guido Pozza and Nicola Canal and Comi, {Gian Carlo} and Gianfranco Lenti and Gianfranco Pagano and Ludovico Bergamini and Walter Troni and Francesco Frigato and Cesare Ravenna and Corrado Mezzina and Roberta Gallato and Danilo Massari and Marino Massarotti and Rita Matano and Francesco Grigoletto and Hank Davis and Monroe Klein",
year = "1983",
month = "7",
doi = "10.1007/BF02581271",
language = "English",
volume = "20",
pages = "265--276",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",

}

TY - JOUR

T1 - Ganglioside treatment in diabetic peripheral neuropathy

T2 - A multicenter trial

AU - Crepaldi, Gaetano

AU - Fedele, Domenico

AU - Tiengo, Antonio

AU - Battistin, Leontino

AU - Negrin, Paolo

AU - Pozza, Guido

AU - Canal, Nicola

AU - Comi, Gian Carlo

AU - Lenti, Gianfranco

AU - Pagano, Gianfranco

AU - Bergamini, Ludovico

AU - Troni, Walter

AU - Frigato, Francesco

AU - Ravenna, Cesare

AU - Mezzina, Corrado

AU - Gallato, Roberta

AU - Massari, Danilo

AU - Massarotti, Marino

AU - Matano, Rita

AU - Grigoletto, Francesco

AU - Davis, Hank

AU - Klein, Monroe

PY - 1983/7

Y1 - 1983/7

N2 - Ganglioside treatment was evaluated with a multicenter, randomized, double-blind, controlled, cross-over vs placebo trial in 140 insulin-treated diabetic subjects with peripheral neuropathy. The patients entered the study when they showed an impairment in at least two of the electroneurographic parameters, and were assigned to two protocols according to the presence and severity of their neurological symptoms. Ninety-seven diabetic subjects with no or mild symptoms were assigned to protocol I, whereas 43 symptomatic patients were assigned to protocol II. The treatment periods lasted 6 weeks with an intermediate washout period of 4 weeks. The treatment consisted in the daily i.m. administration of 20 mg gangliosides or of placebo. Electroneurographic parameters were recorded at the beginning and at the end of each treatment period, whereas clinical and metabolic data (mean daily plasma glucose, glycosuria and glycosylated hemoglobin) were evaluated every three weeks in protocol I and every two weeks in protocol II. No change in the metabolic parameters was observed throughout the trial period. However, the treatment induced a statistically significant improvement of paresthesias (protocol II) and of some electrophysiological parameters; in particular, ganglioside treatment improved MCV of peroneal nerve (p

AB - Ganglioside treatment was evaluated with a multicenter, randomized, double-blind, controlled, cross-over vs placebo trial in 140 insulin-treated diabetic subjects with peripheral neuropathy. The patients entered the study when they showed an impairment in at least two of the electroneurographic parameters, and were assigned to two protocols according to the presence and severity of their neurological symptoms. Ninety-seven diabetic subjects with no or mild symptoms were assigned to protocol I, whereas 43 symptomatic patients were assigned to protocol II. The treatment periods lasted 6 weeks with an intermediate washout period of 4 weeks. The treatment consisted in the daily i.m. administration of 20 mg gangliosides or of placebo. Electroneurographic parameters were recorded at the beginning and at the end of each treatment period, whereas clinical and metabolic data (mean daily plasma glucose, glycosuria and glycosylated hemoglobin) were evaluated every three weeks in protocol I and every two weeks in protocol II. No change in the metabolic parameters was observed throughout the trial period. However, the treatment induced a statistically significant improvement of paresthesias (protocol II) and of some electrophysiological parameters; in particular, ganglioside treatment improved MCV of peroneal nerve (p

KW - Diabetic neuropathy

KW - Gangliosides

KW - Nerve conduction velocity

UR - http://www.scopus.com/inward/record.url?scp=0021090813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021090813&partnerID=8YFLogxK

U2 - 10.1007/BF02581271

DO - 10.1007/BF02581271

M3 - Article

C2 - 6356740

AN - SCOPUS:0021090813

VL - 20

SP - 265

EP - 276

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 3

ER -